Use of surveillance cultures and enteral vancomycin to control methicillin-resistant Staphylococcus aureus in a paediatric intensive care unit

Clinical Microbiology and Infection

Volumn 12, Issue 1, 2006, Pages 35-42

  Thorburn, Kent ^a   Taylor, N ^b   Saladi, S M ^a   van Saene, H K F ^b  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Gut overgrowth; Infection control; MRSA; Paediatric ICU; Surveillance; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFRADINE; COLISTIN; FLUCLOXACILLIN; GLYCOPEPTIDE; LINEZOLID; METICILLIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL OVERGROWTH; BACTERIAL TRANSMISSION; BACTERIUM CARRIER; BACTERIUM CULTURE; CHILD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; HOSPITAL ADMISSION; HOSPITAL POLICY; HUMAN; INFANT; INFECTION CONTROL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOSE SMEAR; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM; SAFETY; STAPHYLOCOCCUS INFECTION; THROAT CULTURE; TISSUE CULTURE;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 33644851116     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01292.x     Document Type: Article

References (46)

1. Benner EJ, Kayser FH. Growing clinical significance of methicillin-resistant Staphylococcus aureus. Lancet 1968; ii: 741-744.
2. Barret FE, McGehe RF, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital: Bacteriologic and epidemiologic observations. N Engl J Med 1968; 279: 441-448.
3. Duckworth G. Controlling methicillin-resistant Staphylococcus aureus. BMJ 2003; 327: 1177-1178.
4. Diekema DJ, Bootsmiller BJ, Vaughn TE et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004; 38: 78-85.
5. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-532.
6. Hill PC, Wong CG, Voss LM et al. Prospective study of 125 cases of Staphylococcus aureus bacteremia in children in New Zealand. Pediatr Infect Dis J 2001; 20: 868-873.
7. Khairulddin N, Bishop L, Lamagni TL et al. Emergence of methicillin resistant Staphylococcus aureus (MRSA) bacteraemia among children in England and Wales, 1990-2001. Arch Dis Child 2004; 89: 378-379.
8. Andersen BM, Lindemann R, Bergh K et al. Spread of methicillin-resistant Staphylococcus aureus in a neonatal intensive unit associated with understaffing, overcrowding and mixing of patients. J Hosp Infect 2002; 50: 18-24.
9. Nambiar S, Herwaldt LA, Singh N. Outbreak of invasive disease caused by methicillin-resistant Staphylococcus aureus in neonates and prevalence in the neonatal intensive care unit. Pediatr Crit Care Med 2003; 4: 220-226.
10. Corbella X, Dominguez MA, Pujol M et al. Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients. Eur J Clin Microbiol Infect Dis 1997; 16: 351-357.
11. Anonymous. Report of a combined Working Party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospital. J Hosp Infect 1998; 39: 253-290.
12. Farrington M, Redpath C, Trundle C et al. Winning the battle but losing the war: Methicillin-resistant Staphylococcus aureus (MRSA) infection at a teaching hospital. Q J Med 1998; 91: 539-548.
13. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Review. In: The Cochrane library, issue 2. Chichester: Wiley, 2005.
14. Parras F, Guerrero MC, Bouza E et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 175-179.
15. Harbarth S, Dharan S, Liassine N et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus outbreaks. Antimicrob Agents Chemother 1999; 43: 1412-1416.
16. Shahin R, Johnson IL, Jamieson F et al. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Arch Pediatr Adolesc Med 1999; 153: 864-868.
17. Coello R, Jimenez J, Garcia M et al. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 200 patients. Eur J Clin Microbiol Infect Dis 1994; 13: 74-81.
18. Silvestri L, Milanese M, Oblach L et al. Enteral vancomycin to control methicillin-resistant Staphylococcus aureus outbreak in mechanically ventilated patients. Am J Infect Control 2002; 30: 391-399.
19. de la Cal MA, Cerda E, van Saene HKF et al. Effectiveness and safety of enteral vancomycin to control endemicity of methicillin-resistant Staphylococcus aureus in a medical/surgical intensive care unit. J Hosp Infect 2004; 56: 175-183.
20. Silvestri L, van Saene HKF, Milanese M et al. Prevention of MRSA pneumonia by oral vancomycin decontamination: A randomised trial. Eur Respir J 2004; 23: 921-926.
21. Sanchez M, Mir N, Canton R et al. The effect of topical vancomycin on acquisition, carriage and infection with methicillin-resistant Staphylococcus aureus in critically ill patients. A double-blind, randomized, placebo-controlled study (abstract J-119). In: Programme and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997: 310.
22. Shann F, Pearson G, Slater A, Wilkinson K. Paediatric index of mortality (PIM): A mortality prediction model for children in intensive care. Intens Care Med 1997; 23: 201-207.
23. Linares J. The VISA/GISA problem: Therapeutic implications. Clin Microbiol Infect 2001; 7: 8-15.
24. de Man P, Verhoeven BA, Verbrugh HA et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973-978.
25. Cunha BA. Effective antibiotic-resistance control strategies. Lancet 2001; 357: 1307-1308.
26. Foca A, Matera G, Berlinghieri MC. Inhibition of endotoxin-induced interleukin 8 release by teicoplanin in human whole blood. Eur J Clin Microbiol Infect Dis 1993; 12: 940-944.
27. Sarginson RE, Taylor N, Reilly N, Baines PB, van Saene HKF. Infection in prolonged pediatric critical illness: A prospective four-year study based on knowledge of the carrier state. Crit Care Med 2004; 32: 839-847.
28. Solis A, Brown D, Hughes J, van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatr Pulmonol 2003; 36: 189-195.
29. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community acquired staphylococcus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23: 255-259.
30. Van Saene H.K.F, Damjanovic V, Alcock S.R. Basics in microbiology for the patient requiring intensive care. Curr Anaest Crit Care 2001; 12: 6-7.
31. Leonard EM, Van Saene HK, Shears P et al. Pathogenesis of colonization and infection in a neonatal surgical unit. Crit Care Med 1990; 18: 264-269.
32. Bignardi G.E, Riley U, Easmon C.S.F. Use of the E-test for methicillin sensitivity testing. J Antimicrob Chemother 1993; 32: 37-43.
33. Denis O, Nonhoff C, Byl B et al. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: Microbiological and clinical features. J Antimicrob Chemother 2002; 50: 383-391.
34. Endtz HP, van den Braak N, van Belkum A et al. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in the Netherlands. J Clin Microbiol 1997; 35: 3026-3031.
35. Hendrix CW, Hammond JMJ, Swoboda SM et al. Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients. Ann Surg 2001; 233: 259-265.
36. Sarginson RE, Taylor N, van Saene HKF. Glossary of terms and definitions. Curr Anaesth Crit Care 2001; 12: 2-5.
37. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140.
38. van Saene HKF, Weir WI, de la Cal MA et al. MRSA - time for a more pragmatic approach? J Hosp Infect 2004; 56: 170-174.
39. Damjanovic V, Connolly CM, van Saene HKF et al. Selective decontamination with nystatin for control of a Candida outbreak in a neonatal intensive care unit. J Hosp Infect 1993; 24: 245-259.
40. Luiten EJT, Hop WCJ, Endtz HP, Bruining HA. Prognostic importance of Gram-negative colonizing preceding pancreatic infection in severe acute pancreatitis. Intens Care Med 1998; 24: 438-445.
41. Chang FY, Singh N, Gayowski T et al. Staphylococcus aureus nasal colonization in patients with cirrhosis: Prospective assessment of association with infection. Infect Control Hosp Epidemiol 1998; 19: 328-332.
42. Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 309-317.
43. Bonten MJM, Gaillard CA, Johanson WG et al. Colonization in patients receiving and not receiving topical antimicrobial prophylaxis. Am J Respir Crit Care Med 1994; 150: 1332-1340.
44. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001; 7: 183-187.
45. Salgado CD, Giannetta ET, Farr BM. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile. Infect Control Hosp Epidemiol 2004; 25: 413-417.
46. Stiefel U, Paterson DL, Pultz NJ et al. Effect of increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect Control Hosp Epidemiol 2004; 25: 380-383.